Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Minority Interest (2017 - 2020)

BeOne Medicines (BEIGF) has disclosed Minority Interest for 4 consecutive years, with $9.1 million as the latest value for Q3 2020.

  • Quarterly Minority Interest fell 42.15% to $9.1 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Sep 2020, down 42.15% year-over-year, with the annual reading at $16.2 million for FY2019, 11.8% up from the prior year.
  • Minority Interest for Q3 2020 was $9.1 million at BeOne Medicines, down from $10.2 million in the prior quarter.
  • The five-year high for Minority Interest was $17.4 million in Q2 2019, with the low at $9.1 million in Q3 2020.
  • Average Minority Interest over 4 years is $14.0 million, with a median of $14.4 million recorded in 2017.
  • The sharpest move saw Minority Interest increased 29.07% in 2019, then crashed 42.15% in 2020.
  • Over 4 years, Minority Interest stood at $14.4 million in 2017, then increased by 0.16% to $14.4 million in 2018, then grew by 11.8% to $16.2 million in 2019, then tumbled by 43.55% to $9.1 million in 2020.
  • According to Business Quant data, Minority Interest over the past three periods came in at $9.1 million, $10.2 million, and $14.8 million for Q3 2020, Q2 2020, and Q1 2020 respectively.